Page Industries share pros and cons: exclusive Jockey India licensee with 50 percent ROE analysed for 2026. Brand monopoly moat, athleisure growth, single licence dependency risk, and premium PE covered.

KPIT Technologies share pros and cons: India’s automotive software pure-play at 30x PE. EV and ADAS tailwind, OEM client base, automotive cycle risks covered.

Tata Elxsi share pros and cons: design-technology services leader with Tata Group backing analysed for 2026. Unique capabilities, growth deceleration risks, automotive domain, and PE concerns covered.

Cyient share pros and cons: engineering services with aerospace and geospatial expertise at reasonable 23x PE analysed for 2026. DLM strategy, low ROE challenge, and domain moats covered.

Polycab India share pros and cons: India’s largest cable company with FMEG growth strategy analysed for 2026. Infrastructure demand, copper sensitivity, Havells competition, and 48x PE valuation covered.

Zydus Lifesciences share pros and cons: India pharma value at cheap 22x PE analysed for 2026. Saroglitazar novel drug innovation, US complex generics, consumer wellness brands, and growth scale challenges covered.

Ipca Laboratories share pros and cons: anti-malarial API global leader in FDA recovery mode analysed for 2026. API market leadership, balanced revenue model, regulatory history, and US re-entry optionality covered.

Natco Pharma share pros and cons: India’s cheapest pharma at 12x PE with Para-IV oncology strategy analysed for 2026. Patent challenge model, exclusivity earnings, lumpy revenue risks, and cheap valuation opportunity covered.

Coal India share pros and cons: world’s largest coal producer at cheap 8x PE and 6.5 percent yield. India energy security role, energy transition risk, and PSU governance constraints covered.

Torrent Power share pros and cons: India’s best private integrated utility analysed for 2026. Ahmedabad distribution, Torrent governance, renewable expansion, PE premium, and debt risks covered.